our Premium Content: News alerts, weekly reports and conference planners

DRUG:

QH104

News alerts, weekly reports and conference planners

Company:

Beijing Qinghui Liannuo Biotechnology, Suzhou Dushu Lake Hospital

Drug class:

γδ TCR modulator, B7-H3-targeted CAR-T immunotherapy

Undisclosed EGFR/B7H3 CAR-T (0)

fhB7H3.CAR-Ts (0)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

BTN2A1/3A1-Fc-CD19scFv (0)

CD7-UCAR-γδT cells (0)

ET1402L1-ARTEMIS T cells (0)

ET206 (0)

GDT002 (0)

Gamma delta T-cells (0)

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

LAVA-051 (0)

LYT-210 (0)

NK/γδ T cell-enriched cell therapy (0)

PF-08046052 (0)

TAK-012 (0)

UTAA06 (0)

anti-CD19-CAR γδT (0)

AVM0703 (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

GD2, PSMA and CD276 CAR-T (0)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

Undisclosed EGFR/B7H3 CAR-T (0)

fhB7H3.CAR-Ts (0)

›

Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (NCT06018363)

Phase 1/2

Dushu Lake Hospital Affiliated to Soochow University

Dushu Lake Hospital Affiliated to Sooch...

Recruiting

Phase 1/2

Dushu Lake Hospital Affiliated to Soochow Unive...

Recruiting

Last update posted :

08/30/2023

Initiation :

06/01/2023

Primary completion :

12/31/2025

Completion :

12/31/2026

IL6 • CD276 • IL10

CD276 expression

QH104

QH104

Trials

Trials